Skip to main content

Advertisement

SpringerLink
Log in

Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Introduction

High level evidence to guide surveillance following curative intent treatment for pancreatic cancer is lacking and this has likely resulted in wide variations in practice. We aim to describe patterns of surveillance and evaluate their impact on outcomes.

Methods

A total of 147 adult patients who received at least one cycle of adjuvant gemcitabine or 5-fluorouracil-based chemotherapy at any one of five British Columbia Cancer Agency centers between 2001 and 2015 were included. Surveillance strategies were classified into two categories: discharged to primary care physicians (PCPs) or follow-up at cancer centers (CC) that included regular clinical assessments, laboratory testing, and/or diagnostic imaging.

Results

Median age at diagnosis was 64 (range 38–85) years and 48% were men. More patients were followed by CC than by PCPs (66 vs. 44%). Among the measured prognostic factors, only patients with advanced tumor stage (T3/4) were more likely to be followed by cancer specialists (78 vs. 62%, P = 0.03), while other patient and disease characteristics were balanced between the two groups. In the entire cohort, 100 (68%) patients had a documented recurrence. Patients followed by CC were more likely to receive palliative chemotherapy at recurrence than those followed by PCPs (58 vs. 34%, respectively, P = 0.03). The median overall survival (OS) was 2.82 (95% CI 2.17–3.32) years in the CC group and 3.35 (95% CI 2.85–5.06) years in the PCP group while the median relapse-free survival (RFS) was 1.4 (95% CI 1.37–1.77) and 2.4 (95% CI 2.07–4.59) years, respectively. On multivariate analysis, there was no significant difference in OS between CC and PCP-based surveillance (HR 1.23; 95% CI 0.74–2.04, P = 0.40); however, RFS favored the PCP group (HR 1.62; 95% CI 1.01–2.56, P = 0.04, for the CC group).

Conclusion

In this population-based analysis, surveillance tests and imaging performed by CC detected recurrences earlier when compared to follow-up by PCPs, but this did not result in OS differences. Patients with more advanced tumors were more likely to be seen at CC. PCPs may play a larger role in the follow-up care of selected low risk patients with resected pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  Google Scholar 

  2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127(12):2893–917.

    Article  CAS  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  Google Scholar 

  4. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039–49.

    Article  CAS  Google Scholar 

  5. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.

    Article  CAS  Google Scholar 

  6. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.

    Article  CAS  Google Scholar 

  7. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(11):1095–103.

    Article  Google Scholar 

  8. Yu Z, Zhong W, Tan ZM, et al. Gemcitabine adjuvant therapy for resected pancreatic cancer: a meta-analysis. Am J Clin Oncol. 2015;38(3):322–5.

    Article  Google Scholar 

  9. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;

  10. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  Google Scholar 

  11. NCCN Guidelines Version 1.2017 Pancreatic Adenocarcinoma Available: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.

  12. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68.

    Article  Google Scholar 

  13. Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541–56.

    Article  Google Scholar 

  14. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221(6):721–31. discussion 731-723

    Article  CAS  Google Scholar 

  15. Sheffield KM, Crowell KT, Lin YL, et al. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19(5):1670–7.

    Article  Google Scholar 

  16. Grunfeld E, Mant D, Yudkin P, et al. Routine follow-up of breast cancer in primary care: randomised trial. BMJ. 1996;313(7058):665–9.

    Article  CAS  Google Scholar 

  17. Grunfeld E, Gray A, Mant D, et al. Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. Br J Cancer. 1999;79(7–8):1227–33.

    Article  CAS  Google Scholar 

  18. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006;24(6):848–55.

    Article  Google Scholar 

  19. Wattchow DA, Weller DP, Esterman A, et al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer. 2006;94(8):1116–21.

    Article  CAS  Google Scholar 

  20. Peixoto RD, Lim HJ, Kim H, et al. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer. 2014;45(3):325–33.

    Article  CAS  Google Scholar 

  21. Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147–56.

    Article  CAS  Google Scholar 

  22. Petzel MQ, Parker NH, Valentine AD, et al. Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors. Ann Surg Oncol. 2012;19(13):4078–84.

    Article  Google Scholar 

  23. Ling D, Korobkin M, Silverman PM. Retrocaval lymphadenopathy mimicking tumor thrombus in the inferior vena cava. Comput Radiol. 1985;9(6):373–6.

    Article  CAS  Google Scholar 

  24. Hewitt M, Greenfield S, Stovall E, et al. From cancer patient to cancer survivor: lost in transition. Washington DC: National Academies Press; 2006.

    Google Scholar 

  25. Furman MJ, Lambert LA, Sullivan ME, et al. Rational follow-up after curative cancer resection. J Clin Oncol. 2013;31(9):1130–3.

    Article  Google Scholar 

  26. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  Google Scholar 

  27. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  Google Scholar 

  28. Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional validation study of the American Joint Commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg. 2017;265(1):185–91.

    Article  Google Scholar 

  29. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110(4):738–44.

    Article  Google Scholar 

  30. Benassai G, Mastrorilli M, Quarto G, et al. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital. 2000;52(3):263–70.

    CAS  PubMed  Google Scholar 

  31. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–5.

    Article  Google Scholar 

  32. Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009;27(17):2855–62.

    Article  Google Scholar 

  33. Kinsella TJ, Seo Y, Willis J, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008;31(5):446–53.

    Article  CAS  Google Scholar 

  34. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24.

    Article  Google Scholar 

  35. Tzeng CW, Abbott DE, Cantor SB, et al. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013;20(7):2197–203.

    Article  Google Scholar 

  36. Witkowski ER, Smith JK, Ragulin-Coyne E, et al. Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg. 2012;16(1):121–8.

    Article  Google Scholar 

  37. http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines/gastrointestinal/pancreas - Follow-Up-pancreas.

  38. Grunfeld E, Julian JA, Pond G, et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol. 2011;29(36):4755–62.

    Article  Google Scholar 

  39. Maly RC, Liu Y, Diamant AL, et al. The impact of primary care physicians on follow-up care of underserved breast cancer survivors. J Am Board Fam Med. 2013;26(6):628–36.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

    Haider H. Samawi, Yaling Yin & Howard J. Lim

  2. Section of Medical Oncology, Tom Baker Cancer Centre, 1331 29 St NW, Calgary, AB, T2N 4N2, Canada

    Winson Y. Cheung

Authors
  1. Haider H. Samawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaling Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard J. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Winson Y. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Winson Y. Cheung.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samawi, H.H., Yin, Y., Lim, H.J. et al. Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. J Gastrointest Canc 49, 429–436 (2018). https://doi.org/10.1007/s12029-017-9988-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-9988-8

Keywords

Search

Navigation